US OptionsDetailed Quotes
PPBT241220C2500
- 2.85
- 0.000.00%
15min DelayClose Nov 27 16:00 ET
0.00High0.00Low
2.85Open2.85Pre Close0 Volume2 Open Interest2.50Strike Price0.00Turnover1192.93%IV64.62%PremiumDec 20, 2024Expiry Date0.75Intrinsic Value100Multiplier22DDays to Expiry2.10Extrinsic Value100Contract SizeAmericanOptions Type0.9409Delta0.0123Gamma1.14Leverage Ratio-0.0263Theta0.0001Rho1.07Eff Leverage0.0009Vega
Purple Biotech Stock Discussion
Sign in to post a comment
$Draganfly (DPRO.US)$ $FOUNDER GROUP LIMITED (FGL.US)$ $Alaunos Therapeutics (TCRT.US)$ $Purple Biotech (PPBT.US)$ $Homestolife (HTLM.US)$ $Pulmatrix (PULM.US)$ $SCWorx (WORX.US)$ $Interactive Strength (TRNR.US)$ $Infobird Software (IFBD.US)$ $Cyclerion Therapeutics (CYCN.US)$ $IM Cannabis (IMCC.US)$ $Unusual Machines (UMAC.US)$ $VCI Global (VCIG.US)$
📊⚡️📊
📊⚡️📊
5
2
10
1
$Alta Global Group (MMA.US)$ $Reviva Pharmaceuticals (RVPH.US)$ $Qualigen Therapeutics (QLGN.US)$ $NOVONIX (NVX.US)$ $Medicus Pharma (MDCX.US)$ $Hepion Pharmaceuticals (HEPA.US)$ $Purple Biotech (PPBT.US)$ $Eterna Therapeutics (ERNA.US)$ $Elong Power (ELPW.US)$ $Venus Concept (VERO.US)$ $Biofrontera (BFRI.US)$ $Exicure (XCUR.US)$
📊⚡️📊
📊⚡️📊
2
1
$Purple Biotech (PPBT.US)$ Reuters· 1 min ago
Purple Biotech Identifies Potential New Serum Biomarker for Its Lead Oncology Therapeutic Candidate Cm24: Associated With 79% Reduction in Risk of Death!
Phase 2 Study of Cm24 in Pancreatic Cancer Expected Q4 2024 Results
Purple Biotech Identifies Potential New Serum Biomarker for Its Lead Oncology Therapeutic Candidate Cm24: Associated With 79% Reduction in Risk of Death!
Phase 2 Study of Cm24 in Pancreatic Cancer Expected Q4 2024 Results
$Purple Biotech (PPBT.US)$ Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK
Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR
Symposium on Molecular Targets and Cancer Therapeutics
CAPTN-3 demonstrates sustained tumor regression in a triple negative breast cancer in-vivo model; A dose dependent activity and a synergistic effect of the engager arms also seen in non-small cell lung cancer patient-derived explants
Lead tribody IM1240 data demonstrated...
Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR
Symposium on Molecular Targets and Cancer Therapeutics
CAPTN-3 demonstrates sustained tumor regression in a triple negative breast cancer in-vivo model; A dose dependent activity and a synergistic effect of the engager arms also seen in non-small cell lung cancer patient-derived explants
Lead tribody IM1240 data demonstrated...
1
$Purple Biotech (PPBT.US)$ Watching for Phase 2 topline data for CM24 Before EOY
1
2
$Purple Biotech (PPBT.US)$ Reuters· just
Purple Biotech Reports Additional Positive Interim Data From Its Randomized Phase 2 Study With Its Lead Oncology Therapeutic Candidate Cm24
Purple Biotech Reports Additional Positive Interim Data From Its Randomized Phase 2 Study With Its Lead Oncology Therapeutic Candidate Cm24
No comment yet
HailTheApocalypse : the draganfly is flying in the wrong direction
House Edge : 000§§